ProQR Therapeutics N.V. (PRQR) 追踪市盈率为负值 -4.2, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 23.4 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -23.84%, 前瞻盈利收益率 4.28%. PEG 0.01 (Peter Lynch 低估标准 ≤1.0).
本页证实的标准:
SharesGrow 综合评分： 57/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -2.8 | -0.03 | 2.04 | 47.60 | - |
| 2017 | -1.6 | -0.53 | 1.77 | -45.62 | - |
| 2018 | -12.7 | 0.34 | 5.04 | 94.83 | - |
| 2019 | -6.4 | -0.23 | 3.42 | 187.60 | - |
| 2020 | -3.7 | 0.11 | 2.46 | 167.18 | - |
| 2021 | -7.4 | -2.31 | 3.97 | 338.65 | - |
| 2022 | -3.8 | 0.74 | 3.69 | 68.88 | - |
| 2023 | -5.2 | 0.08 | 3.17 | 22.28 | - |
| 2024 | -7.5 | 2.63 | 2.36 | 11.05 | - |
| 2025 | -4.5 | -0.38 | 3.67 | 11.85 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $-1.67 | $2.28M | $-39.1M | -1713.5% |
| 2017 | $-1.72 | $-1.53M | $-43.64M | - |
| 2018 | $-1.08 | $4.94M | $-36.89M | -746.7% |
| 2019 | $-1.38 | $1.93M | $-56.75M | -2935.6% |
| 2020 | $-0.93 | $0.00 | $-46.61M | - |
| 2021 | $-0.96 | $1.35M | $-61.68M | -4555.4% |
| 2022 | $-0.91 | $4.04M | $-64.89M | -1607.4% |
| 2023 | $-0.35 | $6.51M | $-28.12M | -431.7% |
| 2024 | $-0.34 | $18.91M | $-27.76M | -146.9% |
| 2025 | $-0.38 | $15.28M | $-40.52M | -265.2% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $-0.51 | $-0.61 – $-0.42 | $23.22M | $21.54M – $24.64M | 7 |
| 2027 | $-0.61 | $-0.86 – $-0.40 | $18.26M | $12.43M – $24.07M | 5 |
| 2028 | $-0.32 | $-0.68 – $0.08 | $69.93M | $67.06M – $72.81M | 4 |
| 2029 | $0.08 | $0.06 – $0.11 | $120.3M | $93.23M – $144.67M | 2 |
| 2030 | $2.42 | $1.71 – $3.06 | $451.4M | $349.84M – $542.87M | 2 |
